Abstract
Objective-To compare the outcome of renal replacement treatment in patients with diabetes mellitus and in non-diabetic patients with end stage renal failure.
Design-Retrospective comparison of cases and matched controls.
Setting-Renal unit, Western Infirmary, Glasgow, providing both dialysis and renal transplantation.
Patients-82 Diabetic patients starting renal replacement treatment between 1979 and 1988, compared with 82 matched non-diabetic controls with renal failure and 39 different matched controls undergoing renal transplantation.
Main outcome measures-Patient characteristics, history of smoking, prevalence of left ventricular hypertrophy and myocardial ischaemia at start of renal replacement treatment; survival of patients with renal replacement treatment and of patients and allografts with renal transplantation.
Results-The overall survival of the diabetic patients during the treatment was 83%, 59%, and 50% at one, three, and five years. Survival was significantly poorer in the diabetic patients than the controls (p<0001). Particularly adverse features for outcome at the start oftreatment were increasing age (p<001) and current cigarette smoking (relative risk (95% confidence interval) 2-28 (0.93 to 4.84), p<005). Deaths were mainly from cardiac and vascular causes. The incidence of peritonitis in patients on continuous ambulatory peritoneal dialysis was the same in diabetic patients and controls (49% in each group remained free of peritonitis after one year), and the survival of renal allografts was not significantly worse in diabetic patients (p<05).
Conclusions-Renal replacement treatment may give good results in diabetic patients, although the outlook remains less favourable than for non-diabetic patients because of coexistent, progressive vascular disease, which is more severe in older patients.
Introduction
The 10 years since this renal unit accepted its first diabetic patients for renal replacement treatment No ischaemia 20 19 Diabetics>controls, McNemar's test, p<0O025. 10 patients per million population per year'2 our diabetic population seems to be selected no more than our other patients with renal failure. Yet survival of these relatively unselected patients with renal replacement treatment was no worse than previous reports of more selected patients.' 313 14 Although survival was better in our patients with insulin dependent than with non-insulin dependent diabetes mellitus (fig 1) , this seemed to be related mainly to their younger age (tables I, VI). We did not attempt to assess the relative contributions to survival of the different forms of renal replacement treatment.
Continuous ambulatory peritoneal dialysis is widely assumed to be preferable to haemodialysis for diabetic patients,7 and almost all our diabetic patients started with this treatment. It is now the form of dialysis chosen by 80% of our patients, with or without diabetes, so our comparative survival data are unlikely to be affected by selection bias in our control group starting continuous ambulatory peritoneal dialysis.
The causes of death recorded in the study ( Most reports show an increased incidence of peritonitis in diabetic patients during continuous ambulatory dialysis.47 One possible explanation for our contrasting result is our choice of subcutaneous insulin as a result of our impression that intraperitoneal insulin led to an increased rate of peritonitis in patients using a disconnect system.6
There are numerous reports of a poorer outcome of renal transplantation in diabetic patients.2' Survival of the allograft was similar in our diabetic patients and controls; survival of the diabetic patients seemed poorer (fig 2) , although in analysis of matched pairs the difference failed to reach significance (table VIII) . We
have not yet lost a transplant because of recurrent diabetic nephropathy, but two cases of such loss more than 12 years after transplantation have been reported.22
In conclusion, we have shown that an integrated programme of dialysis and transplantation may yield good results in younger diabetic patients with renal failure. The prognosis for older patients is less good, mainly because of progressive vascular disease.
ANY QUESTIONS
Is there any radiation emitted by a modern colour television and, ifso, how close can children sit to a set without fear ofdamaging exposure?
In the early days of colour televisions there was some worry over the emission of x rays from the cathode ray tube and thermionic valves. But with a suitable thickness of glass in front of the cathode ray tube and the use of modern electronics x ray emissions are negligible. Most of the measurements on emissions from cathode ray tube display units in recent years have been carried out on visual display units attached to computers, where the operator may sit quite close to the screen for up to eight hours a day. We have carried out several measurements on different designs of computer terminals and found no detectable emissions of x rays. The glass used on the front of the screens, however, is naturally but slightly radioactive, as is the glass in domestic television sets and windows.' The radiation comes from naturally occurring potassium-40, which is also found in humans. The dose level, even in contact with the glass of the television set, is small and comparable with that occurring naturally from another person.
Colour televisions, along with computer monitors, emit non-ionising radiations. These come from the mains (50 Hz) and flyback Is there any benefit in combining aspirin and paracetamol in the treatment of viral pharyngitis orflu?
There are several theoretical reasons why combining these two analgesics might be useful. Firstly, although both drugs are cyclo-oxygenase inhibitors, their mode of action is not identical. Aspirin has a greater peripheral anti-inflammatory effect than paracetamol, which is thought to act mainly centrally. I do not know if these differences are of any clinical relevance. Secondly, combining the two drugs is a way of increasing the total dose without increasing the dose of either drug. Paracetamol has a flat dose-response relation with little increase in effect at doses greater than 1-0-1-5 g. The analgesic effect of aspirin can be increased by increasing the dose, but the risk of adverse effects, especially gastric bleeding, is also increased. I do not know if combining the drugs in practice does in fact increase the analgesic effect or how it compares with doubling the dose of aspirin alone. Thirdly, there is evidence that simultaneous administration of paracetamol and aspirin results in higher blood concentrations of aspirin than the same dose of aspirin given alone. Again the clinical importance of this is unknown, but it could be a way of increasing the analgesic effect of aspirin without increasing the risk of gastric bleeding. There is, of course, a precedent for using the combination in benorylate, a prodrug that is metabolised to aspirin and paracetamol after absorption. - 
